6954.T (6954.T)
Quantitative Summary
DeterministicFinancial health metrics are strong: Piotroski 7/9, Altman Z 19.0 (above 3.0 safe zone threshold).
Generated deterministically from quant metrics and financial statements. Not a recommendation.
Algorithmic Teardown
AI-GeneratedThe company exhibits strong fundamental quality, as evidenced by its ROIC exceeding the cost of capital and a DuPont ROE decomposition that highlights efficient use of assets with robust margins. The net margin at 18.5% is notably high, while asset turnover stands at 0.41x, suggesting effective operational efficiency in generating revenue from assets. Additionally, an equity multiplier of 1.11x indicates moderate leverage without excessive risk. Both the Piotroski F-Score of 7 out of 9 and Altman Z-Score of 19.0 further underscore financial strength with low bankruptcy risk.
In terms of valuation, the current price-to-earnings ratio (P/E) at 34.6x is notably higher than both historical averages and sector peers, suggesting a premium valuation in the market. The discounted cash flow (DCF) fair value calculation implies an intrinsic worth of $8207 per share, which contrasts with the implied growth rate embedded within this model—indicating that investors are pricing in significant future earnings expansion to justify current valuations.
Generated by LLM from quantitative data inputs. May contain inaccuracies. Not investment advice.
DCF Sandbox
InteractiveSensitivity Matrix
| TG ↓ / WACC → | 8% | 10% | 12% |
|---|---|---|---|
| 2% | $9907 | $7405 | $5915 |
| 3% | $11518 | $8207 | $6379 |
| 4% | $13934 | $9277 | $6959 |
Center = base case. Green = >10% upside, Red = >10% downside vs —.
Pre-computed DCF: WACC=10.0%, terminal growth 3%. Fair value $8207 (+0.0%). Not investment advice.
Price Chart with Moving Averages
Quant Health Deep Dive
Profitability & Value Creation
✅ Conservative payout — room for dividend increases.
DuPont Analysis — ROE Decomposition
Breaking down Return on Equity to see how the company generates its ROE — efficiency, margins, or leverage.
Balance Sheet Health
Earnings Surprise History
EPS estimates vs actuals for the most recent reported quarters. Source: yfinance.
Underwater (Drawdown from Peak)
How far below the all-time high the price has been over time. Deeper = more pain for holders.
Rolling 60-Day Beta vs S&P 500 (VOO)
How the stock's sensitivity to market moves changes over time. β > 1 = more volatile than the market.
Fundamentals
6954.T Capital Efficiency
How efficiently does 6954.T convert operating profits into free cash? The FCF Conversion ratio measures the gap between accounting earnings and real cash generation.
6954.T converts 104% of its EBITDA into free cash flow, an exceptional conversion rate indicating an asset-light business model with minimal capital reinvestment drag.
Capital efficiency = Free Cash Flow ÷ EBITDA. Reinvestment = (EBITDA − FCF) ÷ EBITDA. Metrics from latest annual filings. Not investment advice.
Compare 6954.T to Peers
Quant metrics computed deterministically from financial statements and price data. Updated: N/A.
SecuritiesDB provides programmatic data aggregation for informational purposes only. None of the metrics, summaries, or algorithmic flags constitute a recommendation to buy or sell any security.